Alzheimers and Dementia

Eisai-Biogen to advance Alzheimer’s drug, provide fresh hope

(Reuters) - Eisai Co Ltd and Biogen Inc will move forward with late-stage clinical trials of their Alzheimer’s disease drug, BAN2401, and are working with regulators to design the next studies and gain expedited review as a breakthrough therapy. The companies announced this month that despite failing at an earlier stage, the drug slowed Alzheimer’s progression at its highest dose, providing renewed hope in a field littered with failures. In
Biomarkers

Blood Test May Identify Pregnant Women At Risk Of Premature Birth

New research funded by March of Dimes has found biomarkers in maternal blood that accurately identified pregnant women who would go on to deliver babies up to two months prematurely. The findings were published today in the journal Science. This finding is important as doctors do not currently have ways to accurately assess which pregnancies will end with a premature birth, March of Dimes notes. Additionally, using those same blood
cancer

Biomarker may help diagnose lung cancer earlier

(UPI) -- High levels of a protein found in the bloodstreams of lung cancer patients may lead to a method of detecting the disease earlier, and possibly preventing deaths from it, according to a new study. Researchers found high levels of cytoskeleton-associated protein 4, or CKAP4, in the blood of cancer patients predicted their disease. The research was published Tuesday in the American Journal of Pathology. Lung cancer is the
Neurology

FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

The U.S. Food and Drug Administration today permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program. Most patients with a suspected head injury are examined using a neurological scale, called the 15-point Glasgow Coma
Alzheimers and Dementia Biomarkers

A New Clinical Trial for a Novel Brain Injury Biomarker

The challenge with diagnosing chronic traumatic encephalopathy (CTE), a condition that shows up in the overwhelming majority of American football players and other athletes who frequently sustain injuries to the head, is that it can only be diagnosed through an autopsy. Researchers at Medicortex Finland Oy, are working on a diagnostic kit that could detect CTE in a living person with a simple blood test or other body fluids. Actually
Biomarkers

Biomarkers Pinpoint the Effects of Thirdhand Smoke on Liver and Lung Found to Worsen Over Time

Researchers at the University of California, Riverside have found that thirdhand-smoke (THS) exposure has a significant effect on health as early as one month after initiation of exposure – an effect that worsens with time. THS results when exhaled smoke and smoke emanating from the tip of burning cigarettes gets on surfaces such as clothing, hair, homes, and cars. THS has been shown, in mice, to cause type 2 diabetes,
ASCO 2017

Ludwig researchers present new findings at the 2017 ASCO Annual Meeting

Ludwig Cancer Research unveiled the full scope of Ludwig's participation at this year's American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6. Ludwig scientists will present findings on efforts to diagnose and treat a variety of cancers, including melanoma, glioblastoma, multiple myeloma and lymphoma. "The ASCO Annual Meeting provides a unique opportunity for scientists from around the world to share information about new and innovative treatment strategies
Alzheimers and Dementia

Diagnostic biomarkers in saliva show promise in recognizing early Alzheimer’s disease

Your spit may hold a clue to future brain health. Investigators at the Beaumont Research Institute, part of Beaumont Health in Michigan, are hopeful that their study involving small molecules in saliva will help identify those at risk of developing Alzheimer's disease - a neurologic condition predicted to reach epidemic proportions worldwide by 2050. Their study, "Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics" was
Biomarkers Neurology

New Clinical Trial Marks a Significant Accomplishment for Medicortex

Medicortex Finland Oy (www.medicortex.fi), a biotechnology company developing a diagnostic kit for brain injury based on a medical breakthrough biomarker, recently was granted clearance to begin a clinical trial. The trial will consist of patients that are hospitalized due to a head injury. “Collecting and testing human samples in a clinical trial is a significant accomplishment for Medicortex, and represents a meaningful step forward in the development of a fast
Biomarkers

Biomarkers May Help Better Predict Who Will Have a Stroke

People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology. “Identifying people who are at risk for stroke can help us determine who would benefit most from existing or new therapies
Cell Therapy Clinical Trials

Understanding Natural History Studies in Drug Development for Rare Diseases

Q &A with Michelle Berg, Vice President, Patient Advocacy, Abeona Therapeutics Inc. Developing a new drug for patients with a disease, particularly when it’s a disease that affects a relatively small number of patients,  poses unique challenges that do not apply to medical therapies for more prevalent diseases. However, an increasingly common, and particularly important method of addressing the special requirements for developing drugs for treating rare disease is by
Alzheimers and Dementia

The Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Degeneration

As of 2016, we still don’t have a single approved drug to cure or even slow the progression of diseases caused by damage to the brain’s neurons. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) are determined to change that. Today, they announce a $10 million investment to develop effective treatments for frontotemporal degeneration (FTD), a complex form of dementia that affects more than 50,000